Abeona Therapeutics (LTS:0H7R) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0H7R Abeona Therapeutics Inc LTS:0H7R
45 GF Score
Price $7.12
GF Value $19.19
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Abeona Therapeutics SpecialCharges?

Special Charges only applies to banks.

LTS:0H7R
45GF Score
Abeona Therapeutics Inc LTS:0H7R
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abeona Therapeutics (LTS:0H7R) Overvalued in 2026?

Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued. The current stock price of $7.12 is trading 62.9% below its estimated GF Value™ of $19.19. GuruFocus considers Abeona Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0H7R:

  • SpecialCharges:
  • GF Value™: $19.19 vs. price of $7.12 (62.9% below fair value)
  • GF Score™: 45/100 with 8 warning signs

No single metric tells the full story. See the LTS:0H7R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abeona Therapeutics Business Description

Other Exchanges ABEO:USAPCJ:Germany
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
45GF Score

Get the complete analysis for LTS:0H7R

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.12
Price
$19.19
GF Value